Can a Negative Prostate MRI Miss Clinically Significant Cancer?

Yes, it can. A negative prostate MRI is one of the most reassuring results a man can get after a high PSA, but it is not a guarantee.

The scan is very good at ruling out the most aggressive tumors and noticeably less reliable at ruling out every cancer that matters.

That is why the real question after a “clear” scan is usually not about the scan alone. It is about what the doctor did next.

If you or someone in your family was told an MRI looked fine and later received a prostate cancer diagnosis, this article explains how reliable these scans really are, why they sometimes miss cancer, and when that miss can become a prostate cancer malpractice claim in New York.

What a “Negative” Prostate MRI Actually Tells You

Radiologists score prostate MRI findings on a five-point scale called PI-RADS (Prostate Imaging Reporting and Data System):

• PI-RADS 1 or 2 is treated as negative, meaning significant cancer is unlikely.

• PI-RADS 3 is equivocal.

• PI-RADS 4 or 5 means a lesion likely represents significant cancer, and a biopsy is usually recommended.

“Clinically significant” usually means Gleason Grade Group 2 or higher (Gleason 3+4=7 and above). These are tumors with real potential to grow and spread. Grade Group 1 cancers often never cause harm and may be monitored rather than treated.

So a negative MRI says something narrower than “no cancer.” It says “no visible lesion that looks aggressive.” Small or subtle tumors can still be present, and sometimes significant ones are too.

MRI is only one step in a workup that still depends on PSA trends, the physical exam, and biopsy. Our page on how prostate cancer is diagnosed covers that broader process.

Why Some Tumors Don’t Show Up on MRI

Some misses are built into the technology. Tumors can be very small or spread through the gland in a thin pattern that never forms a visible lump. Others sit in areas that are harder to image, such as the front of the gland, the transition zone, or the very top and bottom of the prostate.

A study in Radiology compared MRI reads against prostates removed in surgery. MRI missed 16% of clinically important tumors, and 26% of patients had at least one important tumor go undetected.

Most of the missed tumors were Gleason 3+4, but some were 4+4 or higher. More than half of the missed lesions still could not be seen, or looked benign, even when radiologists went back for a second look.

Patient motion, gas in the rectum, recent biopsy bleeding, and poor technique can all blur what the radiologist sees. A scoring system called PI-QUAL now exists to rate whether a prostate MRI is good enough to rely on.

A High PSA Doesn’t Disappear Because the Scan Was Clean

A negative MRI does not erase a worrying PSA. It is one piece of information that has to be weighed with everything else.

A large prostate can produce a higher PSA without any cancer, so density helps separate those men from men whose PSA is high for the size of their gland. A density of 0.15 ng/mL/cc or higher is widely used as a warning threshold.

The research is consistent on this point. In a Mass General study of 215 men with negative MRIs who had full template biopsies, 15% had clinically significant cancer, and a PSA density above 0.15 was the only independent predictor. The authors concluded that biopsy should not be routinely skipped after a negative MRI.

The Michigan collaborative found that men with a PSA density of 0.1 or higher were about five times more likely to have significant cancer despite a negative scan.

In New York, the state health department reports that Black men are one and a half times more likely to be diagnosed with prostate cancer and twice as likely to die from it. About 17,000 New Yorkers are diagnosed each year.

Our pages on prostate cancer early detection and prostate cancer screening protocols explain how these risk factors shape screening decisions.

What a Reasonable Follow-Up Plan Looks Like

Major urology guidelines do not tell doctors to stop after a negative MRI. European guidance allows biopsy to be skipped when clinical suspicion is low, as a decision shared with the patient. American guidance treats continued suspicion as a reason to keep evaluating. In both, the expectation is the same: follow-up is individualized and written down.

A reasonable plan after a negative MRI usually includes:

• A PSA density calculation based on the measured prostate volume

• A repeat PSA at a set interval

• Attention to the rectal exam findings and family history

• A clear trigger for biopsy or repeat imaging if PSA keeps rising

• A named person responsible for scheduling the next step

When there is no plan, or the patient is simply told everything is fine and never contacted again, that gap is often where these cases begin.

When a Missed Prostate Cancer Becomes Malpractice

A New York malpractice claim generally requires two things.

First, a provider departed from what a reasonably careful doctor in the same specialty would have done.

Second, that departure was a substantial factor in causing real harm. In negative-MRI cases, the patterns we examine most closely include:

• A visible lesion that was misread, under-scored, or not reported

• A poor-quality scan that was read as reliable instead of repeated

• A urologist or primary care doctor who relied on a negative MRI while PSA kept climbing, PSA density was high, or an abnormal rectal exam was documented, and never ordered a biopsy

• Prostate volume never measured, so PSA density was never calculated

• A follow-up PSA or repeat MRI that was recommended but never scheduled, or results that never reached the patient

Causation is often the hardest part. Urology and oncology experts have to show that an earlier diagnosis would likely have meant better treatment options or a better outlook. A short delay in a slow-growing cancer may not have changed much.

A long delay that let a tumor reach a higher grade, spread beyond the prostate, or require harsher treatment often did. The timeline, the grade and stage at diagnosis, and the treatment actually needed all carry weight.

New York’s Filing Deadline

Under CPLR 214-a, a New York malpractice lawsuit generally must be filed within two years and six months. For a negligent failure to diagnose cancer, that period runs from the later of two dates:

• When you knew or reasonably should have known of the mistake and the harm it caused, or

• Your last continuous treatment for the condition

There is an outer limit of seven years from the negligent act.

If a loved one has died, a wrongful death claim generally must be filed within two years of the date of death. Claims involving public hospitals have a much shorter notice requirement.

These deadlines interact in technical ways, so it is worth having your dates reviewed early instead of assuming the longer period applies.

Talk With a New York Cancer Lawyer

Porter Law Group represents patients and families across New York, with offices in Albany, Buffalo, New York City, Rochester, and Syracuse.

If your prostate cancer was diagnosed after a scan that was called negative, our New York cancer lawyers work with board-certified radiology and urology experts to review the images, the PSA history, and the follow-up that should have happened.

You can also see our results in delayed cancer diagnosis cases.

Call 833-888-LATE, email info@porterlawteam.com, or request a free case evaluation.

Attorney advertising. This article provides general information and is not legal or medical advice. Prior results do not guarantee a similar outcome. Filing deadlines depend on the facts of each case.

Frequently Asked Questions

How accurate is a negative prostate MRI?

In research settings, a negative MRI correctly rules out clinically significant cancer about 90% of the time. A 2020 analysis of 42 studies estimated that 7 to 10% of men would miss a significant cancer if they skipped biopsy. In real-world practice the figure can be lower. One Michigan study across 26 practices found 77%.

What does PI-RADS 2 mean on a prostate MRI?

PI-RADS 2 means the radiologist saw no lesion that looks likely to be clinically significant cancer, so the scan is treated as negative. It does not mean there is no cancer. Small, diffuse, or hard-to-image tumors can still be present, which is why PSA trends and other risk factors still matter.

Should I get a biopsy if my MRI is negative but my PSA is high?

That depends on your overall risk and is a decision to make with your urologist. A PSA density of 0.15 or higher, a rising PSA, an abnormal rectal exam, a strong family history, or a genetic risk such as BRCA2 are all reasons doctors may recommend a biopsy despite a negative scan.

What is PSA density, and why does it matter after a negative MRI?

PSA density is your PSA level divided by your prostate’s volume. It helps show whether a high PSA is explained by a large prostate or is high for the gland’s size. Studies show men with negative MRIs and a PSA density above 0.15 face a meaningfully higher risk of significant cancer.

Can I sue if my prostate cancer was missed after a negative MRI in New York?

You may be able to. A claim generally requires showing that a radiologist or doctor fell below the standard of care, such as by misreading a visible lesion or ignoring a rising PSA, and that the delay caused real harm. Expert review is required, and New York’s filing deadlines apply.